Prodigy Biotech

Prodigy is a San Diego-based biotechnology company developing a next-generation protein sequencing platform designed to provide high-throughput, single-molecule resolution of the proteome. By leveraging advanced biochemical and computational methods, the company aims to overcome the limitations of current mass spectrometry and affinity-based proteomics technologies. Their platform is intended to enable deeper insights into protein variants, post-translational modifications, and low-abundance biomarkers, ultimately accelerating drug discovery and clinical diagnostics. The company is backed by prominent venture capital firms and led by veterans from the genomics industry.